Segment Wealth Management LLC Purchases 2,161 Shares of Novo Nordisk A/S (NYSE:NVO)

Segment Wealth Management LLC lifted its holdings in Novo Nordisk A/S (NYSE:NVO) by 1.5% in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 150,038 shares of the company’s stock after buying an additional 2,161 shares during the quarter. Segment Wealth Management LLC’s holdings in Novo Nordisk A/S were worth $12,906,000 at the end of the most recent quarter.

A number of other institutional investors also recently modified their holdings of NVO. International Assets Investment Management LLC boosted its holdings in Novo Nordisk A/S by 10,608.4% during the third quarter. International Assets Investment Management LLC now owns 1,813,571 shares of the company’s stock worth $215,942,000 after buying an additional 1,796,635 shares during the last quarter. DSM Capital Partners LLC raised its holdings in Novo Nordisk A/S by 257,816.0% during the second quarter. DSM Capital Partners LLC now owns 1,593,921 shares of the company’s stock worth $227,516,000 after acquiring an additional 1,593,303 shares in the last quarter. Mediolanum International Funds Ltd bought a new position in shares of Novo Nordisk A/S in the third quarter valued at $98,765,000. Marshall Wace LLP increased its stake in shares of Novo Nordisk A/S by 34,472.1% during the 2nd quarter. Marshall Wace LLP now owns 691,441 shares of the company’s stock worth $98,696,000 after purchasing an additional 689,441 shares during the last quarter. Finally, Wellington Management Group LLP acquired a new position in Novo Nordisk A/S during the third quarter worth approximately $42,017,000. 11.54% of the stock is owned by institutional investors.

Novo Nordisk A/S Trading Down 5.2 %

NVO stock opened at $78.74 on Tuesday. Novo Nordisk A/S has a one year low of $78.17 and a one year high of $148.15. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.75 and a current ratio of 0.94. The company’s 50 day moving average price is $97.76 and its two-hundred day moving average price is $116.89. The company has a market capitalization of $353.33 billion, a PE ratio of 25.48, a price-to-earnings-growth ratio of 0.84 and a beta of 0.45.

Analyst Upgrades and Downgrades

NVO has been the topic of several research analyst reports. BMO Capital Markets dropped their price objective on shares of Novo Nordisk A/S from $156.00 to $105.00 and set an “outperform” rating on the stock in a research report on Monday, December 23rd. StockNews.com cut Novo Nordisk A/S from a “strong-buy” rating to a “buy” rating in a report on Sunday, December 29th. BNP Paribas upgraded Novo Nordisk A/S to a “strong-buy” rating in a report on Monday, December 2nd. Sanford C. Bernstein upgraded shares of Novo Nordisk A/S from an “underperform” rating to a “market perform” rating in a research report on Monday, January 6th. Finally, Cantor Fitzgerald restated an “overweight” rating and issued a $160.00 price target on shares of Novo Nordisk A/S in a report on Wednesday, November 6th. One equities research analyst has rated the stock with a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Buy” and an average target price of $140.20.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.